Business and Finance

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.

The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.

With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.

The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.

The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.

The facility, company says, will be its first that covers end-to-end ADC production.

The company increases its selection of atopic dermatitis treatments in the process.

Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

IQVIA report explores the latest spending tendencies in the United States, while providing additional clarity as to why COVID-19 vaccines and therapeutics continue to experience a decline in volume.

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Study explores how the Inflation Reduction Act’s Drug Price Negotiation Program and its maximum fair prices impact incentives for investments in post-approval activity.

The merger exponentially grows ONO’s oncology pipeline.

The complex will research solutions for manufacturing antibodies, mRNA applications, and more.

The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547.

Company also purchased equipment for 12 good manufacturing practice clean rooms.

Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials.

Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics.

Analysis determines the suggested value of medications for diabetes if they were closer to production costs.

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.